Tag: calcium channel blocker market size

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market for calcium channel blockers has displayed robust growth in the past few years. Currently valued at $15.56 billion in 2024, it is projected that it will expand to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The push factor for this acceleration during the historical period includes a higher prevalence of cardiovascular ailments, an aging demographic, innovations in medical investigation, lifestyle modifications, and enhanced awareness.

The market size for calcium channel blockers is anticipated to experience robust expansion in the forthcoming years, escalating to “$21.59 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This projected growth can be credited to the increasing global incidence of cardiovascular disorders, the prevalence of personalized medicine, enhanced healthcare accessibility, widened indications, regulatory sanctioning, and market development. The trends that will be prominent during this forecast period encompass market expansion, technological progress, regulatory environment, competitive scrutiny, patient inclinations, and awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The calcium channel blocker market’s expansion is projected to be propelled by the growing incidence of cardiovascular ailments. Cardiovascular disease, which impacts the heart or blood vessels, is mitigated by calcium channel blockers (CCBs), reducing the likelihood of heart failure and stroke. Thus, the escalating rates of cardiovascular diseases will spur the demand for calcium channel blockers. For example, as per a report by the American College of Cardiology in August 2022, the four major cardiovascular risk factors are projected to surge in the United States between 2025 and 2060. Diabetes is predicted to see the most significant percentage increase, rising by 39.3% to impact 55 million people, followed by dyslipidemia affecting 126 million (an increase of 27.6%), hypertension impacting 162 million (up by 25.1%), and obesity affecting 126 million (an increment of 18.3%). Moreover, the study noted the most significant estimated rise in rates of cardiovascular disease, with stroke increasing by 33.8% to 15 million and heart failure by 33.4% to 13 million. Ischemic heart disease is also expected to rise by 30.7% to 29 million, and heart attacks by 16.9% to 16 million. Consequently, the growing cardiovascular disease incidence is propelling the calcium channel blocker market’s growth.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Which Emerging Trends And Strategic Shifts Are Shaping The Calcium Channel Blocker Market?

The calcium channel blocker market is witnessing a surge in product innovation as a crucial trend. Major corporations in this market are emphasising on devising innovative products to preserve their prominence in the market. Take for example, CMP Pharma, a pharmaceutical production company situated in the US, released Norliqva in June 2022. This is the first and only oral liquid solution of the besylate salt of amlodipine, a long-lasting calcium channel blocker. The distinguishing aspect of Norliqva is its amlodipine liquid formulation which can be used to manage hypertension in people aged 6 years and older. Norliqva eliminates the complications and inconsistencies associated with crushing or creating amlodipine tablets, assuring a stable dosage and bioequivalence. It is particularly designed for a certain group of patients who need amlodipine but have difficulty swallowing or are incapable of swallowing.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market for calcium channel blockers has displayed robust growth in the past few years. Currently valued at $15.56 billion in 2024, it is projected that it will expand to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The push factor for this acceleration during the historical period includes a higher prevalence of cardiovascular ailments, an aging demographic, innovations in medical investigation, lifestyle modifications, and enhanced awareness.

The market size for calcium channel blockers is anticipated to experience robust expansion in the forthcoming years, escalating to “$21.59 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This projected growth can be credited to the increasing global incidence of cardiovascular disorders, the prevalence of personalized medicine, enhanced healthcare accessibility, widened indications, regulatory sanctioning, and market development. The trends that will be prominent during this forecast period encompass market expansion, technological progress, regulatory environment, competitive scrutiny, patient inclinations, and awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The calcium channel blocker market’s expansion is projected to be propelled by the growing incidence of cardiovascular ailments. Cardiovascular disease, which impacts the heart or blood vessels, is mitigated by calcium channel blockers (CCBs), reducing the likelihood of heart failure and stroke. Thus, the escalating rates of cardiovascular diseases will spur the demand for calcium channel blockers. For example, as per a report by the American College of Cardiology in August 2022, the four major cardiovascular risk factors are projected to surge in the United States between 2025 and 2060. Diabetes is predicted to see the most significant percentage increase, rising by 39.3% to impact 55 million people, followed by dyslipidemia affecting 126 million (an increase of 27.6%), hypertension impacting 162 million (up by 25.1%), and obesity affecting 126 million (an increment of 18.3%). Moreover, the study noted the most significant estimated rise in rates of cardiovascular disease, with stroke increasing by 33.8% to 15 million and heart failure by 33.4% to 13 million. Ischemic heart disease is also expected to rise by 30.7% to 29 million, and heart attacks by 16.9% to 16 million. Consequently, the growing cardiovascular disease incidence is propelling the calcium channel blocker market’s growth.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Which Emerging Trends And Strategic Shifts Are Shaping The Calcium Channel Blocker Market?

The calcium channel blocker market is witnessing a surge in product innovation as a crucial trend. Major corporations in this market are emphasising on devising innovative products to preserve their prominence in the market. Take for example, CMP Pharma, a pharmaceutical production company situated in the US, released Norliqva in June 2022. This is the first and only oral liquid solution of the besylate salt of amlodipine, a long-lasting calcium channel blocker. The distinguishing aspect of Norliqva is its amlodipine liquid formulation which can be used to manage hypertension in people aged 6 years and older. Norliqva eliminates the complications and inconsistencies associated with crushing or creating amlodipine tablets, assuring a stable dosage and bioequivalence. It is particularly designed for a certain group of patients who need amlodipine but have difficulty swallowing or are incapable of swallowing.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market for calcium channel blockers has displayed robust growth in the past few years. Currently valued at $15.56 billion in 2024, it is projected that it will expand to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The push factor for this acceleration during the historical period includes a higher prevalence of cardiovascular ailments, an aging demographic, innovations in medical investigation, lifestyle modifications, and enhanced awareness.

The market size for calcium channel blockers is anticipated to experience robust expansion in the forthcoming years, escalating to “$21.59 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This projected growth can be credited to the increasing global incidence of cardiovascular disorders, the prevalence of personalized medicine, enhanced healthcare accessibility, widened indications, regulatory sanctioning, and market development. The trends that will be prominent during this forecast period encompass market expansion, technological progress, regulatory environment, competitive scrutiny, patient inclinations, and awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The calcium channel blocker market’s expansion is projected to be propelled by the growing incidence of cardiovascular ailments. Cardiovascular disease, which impacts the heart or blood vessels, is mitigated by calcium channel blockers (CCBs), reducing the likelihood of heart failure and stroke. Thus, the escalating rates of cardiovascular diseases will spur the demand for calcium channel blockers. For example, as per a report by the American College of Cardiology in August 2022, the four major cardiovascular risk factors are projected to surge in the United States between 2025 and 2060. Diabetes is predicted to see the most significant percentage increase, rising by 39.3% to impact 55 million people, followed by dyslipidemia affecting 126 million (an increase of 27.6%), hypertension impacting 162 million (up by 25.1%), and obesity affecting 126 million (an increment of 18.3%). Moreover, the study noted the most significant estimated rise in rates of cardiovascular disease, with stroke increasing by 33.8% to 15 million and heart failure by 33.4% to 13 million. Ischemic heart disease is also expected to rise by 30.7% to 29 million, and heart attacks by 16.9% to 16 million. Consequently, the growing cardiovascular disease incidence is propelling the calcium channel blocker market’s growth.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Which Emerging Trends And Strategic Shifts Are Shaping The Calcium Channel Blocker Market?

The calcium channel blocker market is witnessing a surge in product innovation as a crucial trend. Major corporations in this market are emphasising on devising innovative products to preserve their prominence in the market. Take for example, CMP Pharma, a pharmaceutical production company situated in the US, released Norliqva in June 2022. This is the first and only oral liquid solution of the besylate salt of amlodipine, a long-lasting calcium channel blocker. The distinguishing aspect of Norliqva is its amlodipine liquid formulation which can be used to manage hypertension in people aged 6 years and older. Norliqva eliminates the complications and inconsistencies associated with crushing or creating amlodipine tablets, assuring a stable dosage and bioequivalence. It is particularly designed for a certain group of patients who need amlodipine but have difficulty swallowing or are incapable of swallowing.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market size for calcium channel blockers has seen a substantial increase in the past few years. The figures are set to rise from $15.56 billion in 2024 to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The previous growth can be linked to factors such as an increase in cardiovascular disease cases, an elderly population, progress in medical research, lifestyle transformations, and enhanced awareness.

The market for calcium channel blockers is projected to experience robust expansion in the upcoming years. It is anticipated to reach $21.59 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. The projected growth during this period can be ascribed to the increasing worldwide prevalence of cardiovascular diseases, trends in personalized medicine, improved access to healthcare services, expanded indications, regulatory endorsements, and market developments. The forecast period also foresees trends such as market expansion, technological progression, regulatory scenarios, competitive analysis, patient choices, and increased awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The rise in cardiovascular diseases is predicted to propel the calcium channel blocker market’s expansion. Cardiovascular disease, which affects the heart and blood vessels, is increasing in prevalence, leading to a greater demand for calcium channel blockers (CCBs), which help reduce the risk of stroke and heart failure. For example, a report by the American College of Cardiology from August 2022, a US-based non-profit medical group, predicts that all four cardiovascular risk factors will surge from 2025 to 2060 in the United States. The most significant increase is anticipated in diabetes cases, rising by 39.3% to reach 55 million, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also noted that strokes (33.8% increase to 15 million) and heart failure (33.4% to 13 million) are anticipated to see the most significant rises in cardiovascular disease rates, followed by ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million). As a result, the escalating rates of cardiovascular diseases are contributing to the growth of the calcium channel blocker market.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

What Future Market Trends Are Projected For The Calcium Channel Blocker Industry?

The primary trend gaining traction in the calcium channel blocker market is product innovation. Major players in this market are concentrating on the creation of novel products to maintain their market standing. For example, CMP Pharma, a pharmaceutical manufacturer based in the United States, unveiled Norliqva in June 2022. This product is the first and only oral liquid form of the besylate salt of amlodipine, a long-acting calcium channel blocker. The distinctive characteristic of Norliqva is its format – an amlodipine liquid solution, designed to treat hypertension in individuals aged six and above. Unlike conventional treatment methods, Norliqva eradicates the challenges and inconsistencies connected with crushing or fabricating amlodipine tablets, guaranteeing steadiness in dosage and bioequivalence. This product targets a demography of patients who are prescribed amlodipine but struggle with swallowing or are unable to swallow.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Calcium Channel Blocker Market Growth in 2025?

The market for calcium channel blockers has seen robust growth in the past few years. It is projected to expand from $15.56 billion in 2024 to $16.62 billion in 2025, with a CAGR of 6.8%. Factors contributing to growth during the historical period include a rise in cardiovascular diseases, an aging population, progress in medical research, lifestyle changes, and heightened awareness.

What Is the Forecast for the Calcium Channel Blocker Market Size Through 2029?

In the ensuing years, a robust surge is forecasted in the calcium channel blocker market, anticipated to achieve a valuation of $22.07 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 7.4%. This growth can be ascribed to an increasing global incidence of cardiovascular diseases, advancements in personalized medicine, augmented accessibility to healthcare, broadening of indications, regulatory approvals, and market expansion. Key trends in the future include market growth, technological innovations, regulatory environment, competitive evaluation, patient preferences, and increased awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What are the Key Market Players in Calcium Channel Blocker Market and How They’re Evolving?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

What Are the Primary Growth Drivers in the Calcium Channel Blocker Market?

The rising incidence of cardiovascular diseases is anticipated to propel the growth of the calcium channel blocker market. Cardiovascular disease, a condition affecting the heart or blood vessels, oftentimes necessitates the use of calcium channel blockers (CCBs) to decrease the risk of heart failure and stroke. Thus, the escalating incidence of cardiovascular diseases is expected to surge the demand for these blockers. To illustrate, a report from the American College of Cardiology, a non-profit medical association based in the U.S., stated in August 2022 that it is predicted all four cardiovascular risk factors will rise between 2025 and 2060 within the U.S. Diabetes will see the most significant percentage increase, escalating by 39.3% to 55 million individuals. This is followed by dyslipidemia with an increase of 27.6% to 126 million, hypertension with an increase of 25.1% to 162 million, and obesity with an increase of 18.3% to 126 million. The most considerable predicted increases in rates of cardiovascular diseases were found in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), then ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, the rising incidence of cardiovascular diseases is the driving force behind the progress of the calcium channel blocker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

What Are the Leading Segments in the Global Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

What Are the Key Market Trends in the Calcium Channel Blocker Industry?

The calcium channel blocker market is experiencing a surge in popularity for product innovation. Major market players are strategically focusing on creating novel products to maintain their competitive edge. An instance worth noting is the June 2022 introduction of Norliqva by CMP Pharma, a pharmaceutical manufacturer based in the US. This product, a besylate salt of amlodipine, is the first and exclusive oral liquid solution of a long-acting calcium channel blocker. What sets Norliqva apart is its usage as an amlodipine liquid remedy for treating high blood pressure in individuals over the age of six. Norliqva offers a solution to the complexities and inconsistencies associated with crushing or synthesizing amlodipine tablets, ensuring consistent dosage and bioequivalence. It is particularly intended for a segment of patients who need amlodipine but struggle with swallowing or cannot swallow at all.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Is the Regional Outlook for the Calcium Channel Blocker Market?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

This Report Delivers Insight On:

1. How big is the calcium channel blocker market, and how is it changing globally?

2. Who are the major companies in the calcium channel blocker market, and how are they performing?

3. What are the key opportunities and risks in the calcium channel blocker market right now?

4. Which products or customer segments are growing the most in the calcium channel blocker market?

5. What factors are helping or slowing down the growth of the calcium channel blocker market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the calcium channel blocker industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Calcium Channel Blocker Market From 2025 To 2029?

There has been a robust expansion in the market size for calcium channel blocker in the past few years. The projection indicates a rise from $15.56 billion in 2024 to $16.62 billion in 2025, witnessing a compound annual growth rate of 6.8%. The upsurge during the historical period can be linked to a rise in cardiovascular diseases, an aging demographic, breakthroughs in medical studies, shifting lifestyle patterns, and heightened public awareness.

The market for calcium channel blockers is predicted to witness robust expansion in the forthcoming years. It is set to reach a value of $22.07 billion in 2029, growing at a compound annual rate (CAGR) of 7.4%. Factors such as the escalating worldwide incidence of cardiovascular diseases, the trend towards personalized medicine, improved healthcare accessibility, broadened indications, regulatory greenlights, and market enlargement contribute to this growth in the projected period. Notable trends worth observing in the projected period include market growth, advancement in technology, changes in regulatory framework, competitor assessment, patient inclinations, and alertness.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Are the Core Growth Drivers Propelling the Calcium Channel Blocker Market Forward?

The growth of the calcium channel blocker market is anticipated to be fueled by the rising incidence of cardiovascular diseases. These diseases, which affect the heart and blood vessels, typically increase the demand for calcium channel blockers (CCBs). CCBs are employed in reducing the chances of heart failure and stroke. Therefore, a higher rate of cardiovascular diseases directly translates to an increased demand for calcium channel blockers. For example, a report by the American College of Cardiology, a non-profit medical association based in the United States, in August 2022 predicted that all four cardiovascular risk factors would see a rise between 2025 and 2060 in the country. The biggest surge is anticipated in diabetes, with an increase of 39.3% to 55 million individuals, followed by dyslipidemia increasing 27.6% to 126 million, hypertension rising 25.1% to 162 million, and obesity climbing 18.3% to 126 million. Moreover, substantial projected rises have been observed in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), which follows ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, the growing incidence rate of cardiovascular diseases propels the expansion of the calcium channel blocker market.

What Segment Types Define the Calcium Channel Blocker Market Structure?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Calcium Channel Blocker Market?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theCalcium Channel Blocker Industry Evolution?

In the calcium channel blocker market, the primary trend gaining traction is product innovation. Key players in this market are concentrating their efforts on the creation of innovative products to maintain their stronghold in the market. For example, CMP Pharma, an American pharmaceutical manufacturer, introduced Norliqva, the only oral liquid solution of the besylate salt of amlodipine – a potent calcium channel blocker, in June 2022. The uniqueness of Norliqva lies in its embodiment as an amlodipine liquid solution designed to help treat hypertension in individuals aged 6 and up. It eliminates the challenging inconsistencies of crushing or creating amlodipine tablets and ensures precise dosing and bioequivalence. Norliqva is especially beneficial for patients who need amlodipine but struggle with swallowing issues or have an inability to swallow.

View the full report here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Is the Definition of the Calcium Channel Blocker Market?

Calcium channel blockers refer to a type of drug that prevents calcium from entering the muscle cells of the heart and blood vessels. Calcium channel blockers are used to treat a variety of disorders, including high blood pressure, angina, and irregular heartbeats.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theCalcium Channel Blocker Market from 2025 to 2034?

The growth of the calcium channel blocker market is likely to be propelled by the rising incidence rate of cardiovascular diseases. These diseases, which affect the heart or blood vessels, are often combatted with the use of calcium channel blockers (CCBs), which can reduce the chances of heart failure and stroke. Consequently, as cardiovascular disease rates climb, so too will the need for calcium channel blockers. As an example, a study by the American College of Cardiology in August 2022 indicated that all four major cardiovascular risk factors could see increases in the United States between 2025 and 2060. Diabetes is anticipated to experience the highest percentage increase, at 39.3% or 55 million individuals, trailed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Researchers further noted significant projected increases in the rates of stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), along with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). This rise in the incidence rate of cardiovascular diseases is thus fuelling the expansion of the calcium channel blocker market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

#What is the Growth Potential of the Calcium Channel Blocker Market, and How Will It Perform by 2034?

The market size for calcium channel blockers has seen a robust growth in the past few years. The market is projected to expand from $15.56 billion in 2024 to $16.62 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.8%. Factors contributing to the growth during the historic period include a surge in cardiovascular conditions, an aging demographic, advances in medical research, lifestyle changes, and heightened awareness.

The market for calcium channel blockers is projected to exhibit robust growth in the coming years, with an expected value of $22.07 billion by 2029, expanding at a compound annual growth rate of 7.4%. This predicted growth during the forecast period is primarily driven by factors such as the increasing worldwide incidence of cardiovascular diseases, evolving trends in personalized medicine, improved access to healthcare services, broadening of indications, official authorizations, and market enlargement. Key trends anticipated during the forecast period encompass market advancement, technological innovation, regulatory framework, competition assessment, patient choices, and awareness.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

How Are Market Trends and Innovations Revolutionizing theCalcium Channel Blocker Industry in Recent Times?

The emerging trend in the calcium channel blocker market is centered on product innovation. Top-tier companies in this market place great emphasis on creating unique products to maintain their dominance. CMP Pharma, a pharmaceutical manufacturer from the United States, exemplified this trend in June 2022 by launching Norliqva. This product is the first and only besylate salt of amlodipine in oral liquid form. It is a long-lasting calcium channel blocker designed for patients aged 6 and above with high blood pressure. Norliqva offers a practical solution, circumventing the challenges associated with crushing or manipulating amlodipine tablets by providing consistent dosing and bioequivalence. It serves a specific group of patients who have trouble swallowing or are unable to swallow their amlodipine medication.

Which Key Market Players Are Shaping the Future and Growth of theCalcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Are the Core Segments of the Calcium Channel Blocker Market, and How Do They Contribute to Growth?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smpGlobal Calcium Channel Blocker Market, Global Calcium Channel Blocker Market Report, Global Calcium Channel Blocker Market Trends, Global Calcium Channel Blocker Market Size

Browse Through More Reports Similar to the Gobal Calcium Channel Blocker Maret 2025, By The Business Research Company:

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Bipolar Disorder Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the calcium channel blocker market grown over the years?

The market size for calcium channel blockers has seen a robust growth in the past few years. The market is anticipated to expand from $15.56 billion in 2024 to $16.62 billion in 2025, experiencing a compound annual growth rate (CAGR) of 6.8%. The escalation during the historical phase was fostered by factors like the rising prevalence of cardiovascular diseases, an aging population, advancements in medical research, changing lifestyles, and heightened awareness.

What Is the forecasted market size and growth rate for the calcium channel blocker market?

In the upcoming years, the market size of calcium channel blockers is predicted to experience considerable growth, reaching $22.07 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. This forecasted growth can be credited to the escalating worldwide incidence of cardiovascular conditions, trends in individualized treatment, improved healthcare accessibility, indication expansions, regulatory authorizations, and market broadening. The projection period is characterized majorly by market development, technological progress, changes in regulatory frameworks, competitor analysis, patient choices, and increased awareness.

Get your calcium channel blocker market report here!

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What are the major factors driving growth in the calcium channel blocker market?

An upward trend in cardiovascular diseases is anticipated to fuel the expansion of the calcium channel blocker market. These conditions, which affect the heart or blood vessels, often necessitate the use of calcium channel blockers (CCBs) to lower the likelihood of heart failure and stroke. Consequently, a rising rate of cardiovascular diseases suggests an increased need for these drugs. As an example, a study by the American College of Cardiology in August 2022 envisioned a surge in all four cardiovascular risk factors in the United States from 2025 to 2060. The highest anticipated surge is seen in diabetes, expected to grow by 39.3% to 55 million individuals. This is followed by dyslipidemia (rising by 27.6% to 126 million), hypertension (increasing by 25.1% to 162 million), and obesity (growing by 18.3% to 126 million). The report also pointed out an expected substantial rise in rates of cardiovascular diseases, primarily stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million), and heart attacks (16.9% to 16 million). Hence, the escalating rates of cardiovascular diseases are propelling the expansion of the calcium channel blocker market.

What key areas define the segmentation of the global calcium channel blocker Market?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What are the top market players propelling the growth of the calcium channel blocker industry?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

What are the key trends shaping the future of the calcium channel blocker market?

The calcium channel blocker market is witnessing a growing trend of product innovation. To maintain their competitive edge, key players in the market are concentrating on the creation of novel products. An illustration of this is the June 2022 launch of Norliqva by CMP Pharma, a pharmaceutical manufacturer from the US. Norliqva, which is primarily an oral liquid version of besylate salt of amlodipine, is the first and sole long-acting calcium channel blocker of its kind. It is designed for people aged 6 and above who suffer from hypertension. Notably, Norliqva eliminates the challenges and inconsistencies linked to crushing or turning amlodipine tablets into a solution, promising equal dosing and bioequivalence. Furthermore, it is designed for a specific group of patients needing amlodipine who struggle or are incapable of swallowing.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

What regions are dominating the calcium channel blocker market growth?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Bipolar Disorder Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Calcium Channel Blocker Market Over the Forecast Period of 2025 to 2034?

The market size for calcium channel blockers has seen a robust increase in the last few years. Its expansion is projected to rise from $15.56 billion in 2024 to approximately $16.62 billion by the year 2025, with a compound annual growth rate (CAGR) of 6.8%. The growth during the historical period can be credited to a surge in cardiovascular diseases, an aging populace, developments in medical investigations, lifestyle changes, and heightened consciousness.

There is going to be a substantial expansion in the calcium channel blocker market in the years to come. It is expected to reach a value of $22.07 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%. This projected growth within the forecasted period is linked to factors like the increasing worldwide prevalence of cardiovascular diseases, the rise of personalized medicine, broader access to healthcare, the enlargement of indications, regulatory approvals, and market growth. Several trends predicted for the forecasted period encompass market growth, technological progress, regulatory changes, competitive examination, changing patient preferences, and heightened awareness.

Which Factors Are Enhancing the Growth of the calcium channel blocker Market?

The surge in cardiovascular diseases’ prevalence is predicted to propel the calcium channel blocker market’s growth. Cardiovascular disease encompasses conditions impacting the heart or blood vessels. Calcium channel blockers (CCBs) are employed to diminish the likelihood of heart failure and stroke. Therefore, the rise in cardiovascular diseases’ prevalence would result in increased demand for calcium channel blockers. For example, a report by the American College of Cardiology, a non-profit medical association based in the US, forecasted in August 2022 that all four cardiovascular risk factors would see growth from 2025 till 2060 in the United States. Diabetes is expected to see the most significant percentage increase, rising 39.3% to affect 55 million individuals, followed by dyslipidemia (a spike of 27.6% to 126 million), hypertension (ascending 25.1% to 162 million), and obesity (rising 18.3% to 126 million). The researchers also noted that stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) are forecasted to see the most substantial increases in cardiovascular disease rates, with ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million) following suit. Consequently, the rising prevalence of cardiovascular diseases is fuelling the growth of the calcium channel blocker market.

Explore Comprehensive Insights Into The Global Calcium Channel Blocker Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include:

• Pfizer Inc._x000D_

• GlaxoSmithKline plc_x000D_

• Novartis AG_x000D_

• Bausch Health Companies Inc._x000D_

• Lupin Pharmaceuticals Inc._x000D_

What Key Trends Are Currently Impacting the Calcium Channel Blocker Market’s Development?

The prevailing trend of product innovation is bolstering the calcium channel blocker market, with key firms focusing on rolling out novel products to maintain their standing in the market. For example, CMP Pharma, a pharmaceutical constructor based in the US, pioneered the launch of Norliqva, the inaugural and exclusive oral liquid solution form of amlodipine’s besylate salt – a long-lasting calcium channel blocker in June 2022. Norliqva carries a special characteristic, being an amlodipine liquid solution targeted towards treating hypertension in individuals aged 6 years and above. It eliminates the complications and inconsistencies associated with crushing or synthesizing amlodipine tablets, assuring standardized dosage and bioequivalence. Norliqva is designed for a specific group of patients who need amlodipine but struggle with swallowing difficulties or are unable to swallow at all.

Secure Your Global Calcium Channel Blocker Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Market Segments Are Driving Strategic Growth and Trends in the Calcium Channel Blocker Market?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Which Geographical Regions Are Pioneering Growth in the Calcium Channel Blocker Market?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Do Experts Define the Scope of the Calcium Channel Blocker Market?

Calcium channel blockers refer to a type of drug that prevents calcium from entering the muscle cells of the heart and blood vessels. Calcium channel blockers are used to treat a variety of disorders, including high blood pressure, angina, and irregular heartbeats.

Browse Through More Similar Reports By The Business Research Company:

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Bipolar Disorder Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: